BIOLATAM® 2015’s Great Topics

September 14, 2015 Guest Contributor

Arturo CovarrubiasGuest post by Arturo Covarrubias, Chairman of Asembio A.G. and Lawyer and Managing Partner, Covarrubias & Silva Intellectual Property

Biolatam® 2015 is Latin America’s most important biotechnology fair and one of the most important worldwide. Hosting the event in Chile for the first time has been a great motivation and challenge for the Chilean Association of Biotech Companies, ASEMBIO A.G.

The business fair will take place November 16–17 at the CentroParque conference center in Santiago. This event aims at promoting mutual benefits between companies and US, Latin American and European entities, opening potential markets, investments and technological collaborations.

Chile is betting on biotechnology, having an excellent regulatory framework and good economic incentives. The goal of the fair is to satisfy the commercial and information needs of different sectors, and provide the necessary tools for their development.

Biolatam began in Colombia in 2013 with excellent results: it had 710 representatives from 29 countries in attendance, and there were 500 delegates from 298 companies that were part of the partnering program resulting in 839 one-to-one meetings. As well,  the event will feature involvement of 17 international investment funds, with a commercial zone composed of 23 speakers.

In Chile we expect attendance by over 800 people and companies to join in our efforts to position the world of biotechnology in a relevant way.

Biolatam 2015 will convene Latin America’s most important companies and institutions from fields such as pharmaceuticals, food, cosmetics, veterinary science, chemistry, and the energy industry, among others. In the two days of activities, the fair will support the development of science and technology through program offerings, one-to-one partnering meetings, and a commercial fair.

What topics will gather us together?

The Biolatam program features topics that raise great interest such as a public policy panel that will discuss how alliances with the private sector operate to support the development of biotechnology. Another related theme will be “public acquisition of innovative technology,” aimed at strengthening the development of new markets from the perspective of demand, through public hiring.  

In order to deeply analyze the companies’ search for funding, there will be an investment panel that will also provide opportunities for the internationalization of companies, entitled “Creation of Innovation Ecosystems and Biotech Entrepreneurship.”

In terms of business areas, the 2015 agenda will also deal with bio foods, bio-economics, bio-similar tech, and Veterinary-Aquaculture.

There will be also a panel on intellectual property, and presentations of success stories in Chile, and a very interesting opportunity for inquiring about the work of universities in this area.

Biolatam 2015 is co-organized by Asembio and Spain’s Association of Bio-companies (ASEBIO), and it is also supported by ProChile and its sector-related brand, Chilebiotech, that gathers together national biotech companies, being an example of public-private cooperation.

The event is organized by EBD Group, and ICEX foreign trade institute, and Spain’s center for technological and industrial development CDTI are also part of this event.

The event will also have scholars, researchers and international investors in attendance, making Biolatam 2015 a key opportunity for strengthening the relationship between biotechnology and business, from Chile to the world.

 

Register for Biolatam before September 21, 2015 and save USD 200. Partnering opens October 5.

blt15_banner_220x136 (1)

Read more...

Previous Article
BioPharm America™ 2015 – Day 1 Highlights
BioPharm America™ 2015 – Day 1 Highlights

The eighth edition of BioPharm America™ 2015 kicked off today in Boston. An estimated 800 biotech and pharm...

Next Article
The Need in Diabetic Kidney Disease
The Need in Diabetic Kidney Disease

Guest post by James F. List, MD, PhD, Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Re...